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Abstract Human donor skin allografts are suitable
and much used temporary biological (burn) wound
dressings. They prepare the excised wound bed for
ﬁnal autografting and form an excellent substrate for
revascularisation and for the formation of granulation
tissue. Two preservation methods, glycerol preserva-
tion and cryopreservation, are commonly used by
tissue banks for the long-term storage of skin grafts.
The burn surgeons of the Queen Astrid Military
Hospitalpreferentiallyusepartlyviablecryopreserved
skin allografts. After mandatory 14-day bacterial and
mycological culture, however, approximately 15% of
the cryopreserved skin allografts cannot be released
from quarantine because of positive culture. To
maximize the use of our scarce and precious donor
skin, we developed a glycerolisation-based recovery
method for these culture positive cryopreserved allo-
grafts. The inactivation and preservation method,
described in this paper, allowed for an efﬁcient
inactivation of the colonising bacteria and fungi, with
the exception of spore-formers, and did not inﬂuence
the structural and functional aspects of the skin
allografts.
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Human allograft skin is generally used to effect a
temporary (it will mostly be rejected) wound closure
on full thickness (burn) wounds. It acts as a
mechanical and biological barrier and thus decreases
the loss of water, protein, and heat through the (burn)
wound (Mackie 2002; Kearney 2005; Leon-Villapa-
los et al. 2010). Human allograft skin can be
preserved by numerous methods: cool storage, cryo-
preservation, lyophilisation and dehydration (e.g.
glycerolisation). These methods amount to different
ranges of allograft skin viability, integrity and
immunogenicity. In some cases a certain level of
allograft skin viability, integrity and permeability is
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DOI 10.1007/s10561-011-9244-6required, but often skin allografts do not need to be
viable at any expense.
Glycerol or propylene glycol preserved allograft
skin, for example, is non-viable and has been used
successfully in burn surgery for decades (Kreis et al.
1989; de Backere 1994; Huang et al. 2004; Khoo
et al. 2010). Glycerolisation was shown to attenuate
allograft antigenicity (Hettich et al. 1994; Richters
et al. 1997), and thus extend the period of graft take,
and to inhibit bacteria and viruses (Marshall et al.
1995; Saegeman et al. 2008). On the down side,
glycerolized skin tends to be more rigid than fresh or
cryopreserved skin. Hence, glycerolised donor skin is
usually not the ﬁrst choice of temporary biological
dressing of the burn surgeons of the Burn Wound
Centre of the Queen Astrid Military Hospital (BWC-
QAMH).
Cryopreservation has been shown to maintain a
degree of viability and the basic physiochemical and
permeability properties of fresh human skin (Aggar-
wal et al. 1985). First reports of frozen skin storage
date from before the Second World War (Mider and
Morton 1939). In 1952, Billingham and Medawar
described the cryopreservation of skin using glycerol
as cryoprotectant. Since then many protocols for skin
cryopreservation have been developed, based on the
use of a variety of cryoprotectants and constant-rate
cooling using commercially available programmable
controlled-rate freezers (Biagini et al. 1979; Kets
et al.1985; Kearney et al. 1990; Ingham et al. 1993;
Bravo et al.2000; Alotto et al. 2002; Franchini et al.
2009; Pianigiani et al. 2010). The physicians in our
centre have the experience that cryopreserved and
partly viable donor skin allografts generate extra
beneﬁcial effects, mainly a better up granulation of
the wound bed in comparison with glycerolised skin.
They also observed that partly viable cryopreserved
allograft skin stimulates wound healing in superﬁcial
burn wounds in children, thus preventing autograft-
ing. This could be due to the fact that living skin cells
can deliver organisational signals or growth factors to
the wound bed, thus mediating the formation of
granulation tissue or the stimulation of wound healing
(Galkowska et al. 2006) in the same way as do
cultured allogenic keratinocytes and ﬁbroblasts
(Roseeuw et al. 1990; Duinslaeger et al. 1996;
Goedkoop et al. 2010). Down side of the cryopres-
ervation methods, however, is that they tend to
support bacterial and fungal survival, which can be
problematic in the case of skin allograft preservation.
The only variables signiﬁcantly affecting microbio-
logical contamination of donor skin allografts are the
type of donor (live or dead) and the type of
processing (cryo- or glycerol preservation), with
highest levels of contamination found in cryopre-
served cadaveric donor skin (Pianigiani et al. 2010).
In contrast to some other harvested donor tissues (e.g.
bone, tendons and heart valves), skin tissue is
inherently colonised by skin associated micro-organ-
isms and thus non-sterile at the time of harvesting.
Superﬁcial decontamination of the donor’s skin
before harvesting, using antiseptics, is not indefecti-
ble. Therefore, in the BWC-QAMH, freshly har-
vested (post mortem) donor skin is collected in an
antibiotics containing transport solution. This trans-
port solution is composed of 800 ml custom made
Medium for Culturing of Epithelial Cells (MCEC,
Gibco Invitrogen Corporation) supplemented with
200 ml of custom made Cambridge Antibiotic Solu-
tion (CAS, Inverclyde Biologicals). MCEC consists
of 3:1 ratio of DMEM/Ham’s F12 Nutrient mix and
10.6 g/l sodium bicarbonate, while CAS consists of
Gentamicin sulphate (4 g/l), Primaxin (0.2 g/l), Poly-
myxin B (0.2 g/l), Vancomycin (0.05 g/l) and Nys-
tatin (2,500,000 U/l) in Medium 199 with 25 mM
HEPES. The harvested donor skin allografts are kept
in this transport solution (static container) for min-
imum 24 h (max. 72 h) at 2–8C, before further
processing.
The European Human Cell and Tissue Directives
(2004/23/CE, 2006/17/CE and 2006/86/CE) were
recently (December 19, 2008) transposed to Belgian
Law. To be accredited, Belgian banks for human
body materials have to comply with quality and
safety criteria deﬁned in Royal Decrees (September
28, 2009). In addition, the Belgian Superior Health
Council published (October 1, 2008) quality- and
safety criteria for human skin allografts. The skin
bank of the Queen Astrid Military Hospital is EN ISO
9001: 2008 certiﬁed for the full scope of its activities.
Implementing this kind of relevant Quality Manage-
ment Systems is important, also for tissue bankers
(von Versen et al. 2000).
In Belgium, human donor skin allografts are tested
for bacterial and mycological contamination using a
protocol based on 14-day microbiological cultures.
Culture-positive skin allografts can only be released
for clinical use if growth of non-pathogens appeared
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123post 7-days of culture. In our skin bank this results in
a donor rejection rate (due to positive cultures) of
approximately 15% of cryopreserved skin donations,
which is in line with the expectations (Rooney et al.
2008). The CAS containing transport solution was
(since it’s introduction in 2009) not capable of
decontaminating the harvested fresh donor skin in 5
of 34 (14.7%) skin donations. The drug sensitivity
patterns revealed that these bacteria were sensitive (in
vitro) to at least one of the antibiotics present in the
CAS-cocktail. As to why the cocktail was not
efﬁcient in some cases, we can think of two likely
causes. First of all, bacteria can be hidden deep into
the harvested skin (e.g. in the dept of the hair-
follicles) where the antibiotics can’t reach them in
due time and, secondly, the optimal operating tem-
perature of these antibiotics is much closer to 36C
than to 2–8C.
Recently, we decided to develop and implement a
recovery procedure for the cryopreserved skin allo-
grafts that tested positive for bacteria and fungi.
Multiple publications describe the antimicrobial
effect of glycerol and the use of glycerol as an
inactivation agent for culture positive skin allografts
(de Backere 1994; Hoekstra et al.1994; van Baare
et al. 1994; Marshall et al. 1995; Richters et al. 1996;
Mackie 1997; Saegeman et al. 2008). The hitherto
published glycerol preservation and decontamination
methods generally use high glycerol concentrations
and elevated incubation temperatures and periods.
We used the most recently published glycerol inac-
tivation protocol (Saegeman et al. 2008) as a starting
point for our own development. Saegeman and co-
workers investigated the inhibiting effect of glycerol
on bacterial suspensions (not on contaminated skin
samples) in relation to the glycerol concentration and
incubation temperature and time. They observed that
no bacterium, with the exception of one spore-former
(Bacillus subtilis) survived more than 14 days in the
test-tubes with 85% glycerol at 36C.
We transposed these ﬁndings to an inactivation
method for the bacteria and fungi in our culture
positive cryopreserved skin allografts. Twenty-one
thawed (water bath at 37C) culture positive skin
donations were incubated in 50% glycerol (Pharma
Belgium) in Hartmann’s solution (Baxter) for 2–24 h
at 36C, followed by long-term storage in 85%
glycerol in Hartmann’s solution at 36C (Fig. 1).
Skin allografts had been previously routinely
cryopreserved in 30% glycerol in Hartmann’s solu-
tion at\-135C (vapour of liquid nitrogen) (Kets
et al. 1985).
After 5–6 weeks of incubation, several represen-
tative samples of 10–20 cm
2 each were rinsed in
0.9% NaCl and submitted to 14-day bacteriological
and mycological cultures in thioglycolate (with
resazurine, bioMe ´rieux) and Sabouraud (bioMe ´rieux)
broth, respectively. In case of a positive culture, the
85% glycerol solution was renewed and incubation at
36C was resumed. After 5–6 months new samples
Fig. 1 Incubation of skin allografts in 85% glycerol at 36C
Fig. 2 A vial containing glycerolised skin allografts and
labelled with donor references, lot number, sizes and expiry
date
Cell Tissue Bank (2012) 13:1–7 3
123were taken and tested. A skin donation was released
and transfered to ﬁnal sterile (closed and locked)
storage recipients (Fig. 2) upon negative 14-day
cultures. Since the glycerolisation procedure had
signiﬁcantly reduced the initial donor skin surface (up
to 15%), skin allografts were remeasured before ﬁnal
packaging.
After 5–6 months all donations scored negative in
14-day bacterial and mycological testing, except one
(containing Bacillus sp.), which was deﬁnitively
rejected and destroyed (Table 1). The structural
integrity of the rehydrated glycerolisation-recovered
cryopreserved skin allografts was evaluated. Sections
(Bouin ﬁxation followed by haematoxylin eosin
Table 1 Glycerol decontamination of skin allografts positive for bacteria and fungi
Donor
code
14-day bacteriological and mycological culture
Before glycerolisation 5–6 week
glycerolisation
5–6 month glycerolisation
Transposed
Saegeman
protocol
08 010 Pseudomonas aeruginosa No growth Not done
08 019 Staphylococcus capitis No growth Not done
08 031 Candida albicans No growth Not done
08 033 Staphylococcus epidermidis No growth Not done
08 034 Proteus mirabilis, Pseudomonas aeruginosa No growth Not done
08 036 Escherichia coli No growth Not done
08 037 Pseudomonas aeruginosa No growth Not done
08 038 Enterobacter cloacae No growth Not done
08 039 Staphylococcus epidermidis, Staphylococcus capitis No growth Not done
08 040 Klebsiella pneumoniae, Escherichia coli, Enterococcus
faecalis, Staphylococcus capitis, Staphylococcus
haemolyticus
No growth Not done
08 042 Staphylococcus aureus No growth Not done
08 043 Staphylococcus apidermidis, Candida albicans No growth Not done
08 047 Proteus mirabilis, Staphylococcus aureus, Candida albicans No growth Not done
08 050 Staphylococcus epidermidis No growth Not done
08 051 Staphylococcus epidermidis, Candida albicans No growth Not done
08 052 Candida glabrata No growth Not done
08 053 Staphylococcus capitis No growth Not done
08 054 Staphylococcus epidermidis, Staphylococcus warneri No growth Not done
08 056 Staphylococcus epidermidis Staphylococcus
epidermidis
Bacillus sp. (skin graft
was rejected and
destroyed)
08 062 Staphylococcus capitis No growth Not done
09 001 Klebsiella pneumoniae No growth Not done
Optimised
Saegeman
protocol
09 017 Escherichia coli No growth Not done
09 018 Escherichia coli No growth Not done
09 023 Staphylococcus epidermidis Staphylococcus
epidermidis
Bacillus sp. (skin graft
was rejected and
destroyed)
09 034 Staphylococcus epidermidis No growth Not done
09 050 Candida albicans No growth Not done
10 004 Candida albicans, Enterococcus faecum No growth Not done
10 005 Candida albicans No growth Not done
10 015 Clostridium perfringens No growth Not done
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123staining and PAS reaction) of ‘‘direct glycerolisation
only’’, ‘‘direct cryopreservation only’’ and ‘‘glycer-
olisation after cryopreservation’’ skin samples were
evaluated under a microscope and compared (blind)
by an experienced dermato-pathologist. This evalu-
ation was based on the pigmentation, presence and
integrity of hair follicles and their associated muscles,
sweat and sebaceous glands, and the dermal-epider-
mal junction and the presence of apoptotic and/or
necrotic cells, sentinels of local tissue stress and
inﬂammation. No differences were observed between
the structural features of the allografts that were
immediately glycerolised or only cryopreserved and
those that were cryopreserved prior to glycerolisa-
tion. Hair follicles and sweat and sebaceous glands
were clearly present. The samples harboured neither
apoptotic nor necrotic cells and showed a normal
pigmentation and an intact dermal-epidermal junc-
tion. A more elaborate description and discussion on
the functional and structural integrity of those retain
samples was published earlier in this journal by
Verbeken et al. (2010).
Upon this satisfactory structural and histological
evaluation, our burn surgeons started to use the
recovered allografts in routine. Surprisingly, they
observed that the grafts did not resist well to shearing
forces when meshed (skin is fenestrated to allow
drainage and expansion); the epithelium detached
from the dermis (epidermolysis) once rinsed in
physiological solution (0.9% NaCl) prior to use.
Because the epidermis is not an absolute requirement
for the proper functioning of meshed allograft skin,
surgeons reported this as a minor event without
clinical impact for the grafted patients. We preferred,
however, to further optimise our glycerolisation-
recovery protocol and to solve the epidermolysis
problem. We suspected that epidermolysis was
mainly due to the long storage at relatively high
temperature (36C). Therefore we reduced the 50%
glycerol incubation temperature to 2–8C and
reduced the 85% glycerol incubation period at 36C
to 2.5 h, followed by long time incubation in 85%
glycerol at 2–8C. Eight culture positive skin dona-
tions were treated according to this modiﬁed
Fig. 3 Micrograph (2003) of a haematoxylin eosin and PAS
reaction stained section of a rehydrated skin sample that was
thawed after 10 years of cryopreservation at\-135C
Fig. 4 Micrograph (2003) of a haematoxylin eosin and PAS
reaction stained section of a rehydrated skin sample that was
glycerolised, without previous cryopreservation
Fig. 5 Micrograph (2003) of a haematoxylin eosin and PAS
reaction stained section of a rehydrated skin sample that was
thawed after 14 weeks of cryopreservation at\-135C and
subsequently glycerolised (optimised protocol)
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123protocol. With the exception of one (again containing
Bacillus sp.), all skin donations were successfully
decontaminated (Table 1) and, as could be expected,
all samples exhibited normal structural aspects.
Microscopical pictures show a piece of hydrated skin
that was only cryopreserved (Fig. 3), one that was
only glycerolised (Fig. 4) and one that was glycero-
lised (‘‘decontaminating—glycerolisation’’) after
thawing (Fig. 5). This time the surgeons who used
the skin grafts and the technicians and nurses who
processed and prepared the grafts did not observe any
mechanical or structural abnormalities, such as
epidermolysis, when recovered skin allografts were
meshed and rehydrated. Preliminary clinical obser-
vations (7555 cm
2 of glycerolisation-recovered skin
was grafted) indicate that there are no effects on the
functional characteristics of the donor skin.
Although the physicians of the BWC-QAMH
usually prefer to use the more elastic, viable and
presumably wound healing-stimulating cryopre-
served skin, for some indications they opt for the
less immunogenic glycerolised skin. Today, the skin
bank can provide them with both types of allograft
skin whilst recycling most of the culture positive
cryopreserved skin allografts. Contamination with
spore-formers remains however problematic. This
results in an optimal use of the scarce and precious
harvested donor skin (Fig. 6). The described proto-
col could also be of interest to tissue bankers using
glycerolisation as main or sole method of preserva-
tion or to researchers involved in the development of
human skin equivalents (Richters et al. 2008;
Bo ¨ttcher-Haberzeth et al. 2010; van der Veen et al.
2010).
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
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